51,200 Shares in Catalyst Pharmaceuticals, Inc. $CPRX Acquired by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 51,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,268,000.

Several other hedge funds have also bought and sold shares of CPRX. Advisory Services Network LLC purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $39,000. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $40,000. Clearstead Advisors LLC raised its position in shares of Catalyst Pharmaceuticals by 192.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 55.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 630 shares during the last quarter. Finally, Financial Life Planners bought a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth $42,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $31.45 on Friday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 18.07, a PEG ratio of 0.96 and a beta of 0.74. The firm has a 50 day moving average price of $30.93 and a 200-day moving average price of $26.50.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CPRX. Zacks Research lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. HC Wainwright cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Finally, Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).